keyword
MENU ▼
Read by QxMD icon Read
search

Neuro-oncology

keyword
https://www.readbyqxmd.com/read/29147859/initial-psycho-oncological-counselling-in-neuro-oncology-analysis-of-topics-and-needs-of-brain-tumour-patients
#1
Stephanie Schipmann, Eric Suero Molina, Anna Frasch, Walter Stummer, Dorothee Wiewrodt
Diagnosis of a brain tumour is associated with a tremendous disruption of emotional, physical and social well-being. Due to the complexity of the disease and the affection of the central organ, the brain, brain tumour patients differ from other cancer patients. The purpose of this study was to evaluate the concerns and burdens presented by brain tumour patients during their initial psycho-oncological consultation. We performed a retrospective analysis of 53 patients with the diagnosis of either benign or malignant brain tumour, seeking counsel by a neurosurgeon specialised in psycho-oncology...
November 17, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29143276/long-term-impact-of-temozolomide-on-1p-19q-codeleted-low-grade-glioma-growth-kinetics
#2
C Izquierdo, A Alentorn, A Idbaih, M Simó, G Kaloshi, D Ricard, M Barritault, D Meyronet, J Bruna, J Honnorat, J Y Delattre, F Ducray
Although upfront temozolomide (TMZ) has been widely-used to treat 1p/19q-codeleted diffuse low-grade gliomas (LGG), its long-term impact on the growth kinetics of these tumors has not been determined. Based on serial magnetic resonance images we retrospectively evaluated the evolution of the mean tumor diameter (MTD) in 36 progressive 1p/19q-codeleted LGG treated with upfront TMZ. After TMZ onset, all but two patients (94.4%) presented a progressive MTD decrease that lasted for a median duration of 23 months (range 3-114)...
November 15, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29141278/a-survey-of-the-neuro-oncology-landscape
#3
REVIEW
Rimas V Lukas, Jing Wu, Mahua Dey, Robin A Buerki, Richard W Byrne, George J Dohrmann
The field of neuro-oncology is evolving rapidly. Many important advances have recently been reported, and other promising investigations have the potential to soon make substantial impacts in the field, especially in the areas of high-grade gliomas and brain metastases. We present an overview of the current status of this field, highlighting the key recent advances as well as representative work of key clinical investigations, since these concepts have the potential to influence clinical management if they are demonstrated to be safe and efficacious...
October 31, 2017: Journal of Clinical Neurology
https://www.readbyqxmd.com/read/29135901/clinical-factors-associated-with-pediatric-brain-neoplasms-versus-primary-headache-a-case-control-analysis
#4
David C Sheridan, Bethany Waites, Bradley Lezak, Robert J Coryell, Kellie J Nazemi, Amber L Lin, Rongwei Fu, Matthew L Hansen
OBJECTIVE: Pediatric headaches are a common presentation to emergency departments accounting for almost half a million annual visits. Providers are left with the difficult task of deciding who has a secondary headache etiology that warrants neuroimaging. METHODS: We conducted a retrospective case-control study. Patients from a pediatric neuro-oncology clinic database with brain cancer and a headache at presentation were identified as cases. Controls were patients from 2 local pediatric tertiary care emergency departments with a final diagnosis of headache after negative neuroimaging...
November 14, 2017: Pediatric Emergency Care
https://www.readbyqxmd.com/read/29125714/prognostic-awareness-and-communication-preferences-among-caregivers-of-patients-with-malignant-glioma
#5
A J Applebaum, K Buda, M Kryza-Lacombe, J B Buthorn, R Walker, K M Shaffer, T A D'Agostino, E L Diamond
OBJECTIVE: Malignant glioma is a devastating neuro-oncologic disease with almost invariably poor prognosis, yet many families facing malignant glioma have poor prognostic awareness (PA), or the awareness of the patient's incurable disease and shortened life-expectancy. Accurate PA is associated with favorable medical outcomes at the end-of-life for patients and psychosocial outcomes for informal caregivers (ICs) through bereavement. To date, however, no study has specifically examined PA among MG ICs and the information they receive that shapes their awareness...
November 10, 2017: Psycho-oncology
https://www.readbyqxmd.com/read/29122306/carmustine-wafer-implantation-for-high-grade-gliomas-evidence-based-safety-efficacy-and-practical-recommendations-from-the-neuro-oncology-club-of-the-french-society-of-neurosurgery
#6
REVIEW
A Roux, F Caire, J Guyotat, P Menei, P Metellus, J Pallud
There is a growing body of evidence that carmustine wafer implantation during surgery is an effective therapeutic adjunct to the standard combined radio-chemotherapy regimen using temozolomide in newly diagnosed and recurrent high-grade glioma patient management with a statistically significant survival benefit demonstrated across several randomized clinical trials, as well as prospective and retrospective studies (grade A recommendation). Compelling clinical data also support the safety of carmustine wafer implantation (grade A recommendation) in these patients and suggest that observed adverse events can be avoided in experienced neurosurgeon hands...
November 6, 2017: Neuro-Chirurgie
https://www.readbyqxmd.com/read/29121778/intraoperative-image-guided-surgery-in-neuro-oncology-with-specific-focus-on-high-grade-gliomas
#7
Syed O Mahboob, Muftah Eljamel
Surgery is paramount in glioma management and extent of resection is an independent significant prognostic factor. However, these tumors are often invisible intraoperatively. Hence imaging plays an important role in surgical guidance. A critical literature review, using MEDLINE/PubMed service was carried out. It demonstrated a gross total resection (GTR) with neuronavigation (NNS) of 31-36%, adding 5-aminolevulinic acid or fluorescein fluorescence, or intraoperative ultrasound or MRI improved GTR to 69.1, 84...
November 2017: Future Oncology
https://www.readbyqxmd.com/read/29118907/nova1-acts-as-an-oncogene-in-osteosarcoma
#8
Chengzhen Li, Ying He, Haijing Ma, Seongho Han
Osteosarcoma is one of the most common bone tumors in young patients. NOVA1 (neuro-oncological ventral antigen 1) is a neuron-specific RNA binding-protein and belongs to the Nova family. Previous studies showed that NOVA1 played crucial roles in the development of several tumors. The objective of our study was to study the role of NOVA1 in the osteosarcoma. In our study, we showed that NOVA1 expression was upregulated in osteosarcoma cell lines and tissues. The expression of NOVA1 was upregulated in 22 (22/30; 73%) osteosarcoma cases compared to that in the adjacent tissues...
2017: American Journal of Translational Research
https://www.readbyqxmd.com/read/29114999/comparison-between-site-and-central-radiological-assessments-for-patients-with-recurrent-glioblastoma-on-a-clinical-trial
#9
Kathryn M Field, Greg Fitt, Mark A Rosenthal, John Simes, Anna K Nowak, Elizabeth H Barnes, Kate Sawkins, Christine Goh, Bradford A Moffat, Simon Salinas, Lawrence Cher, Helen Wheeler, Elizabeth J Hovey, Pramit M Phal
AIM: Assessment of magnetic resonance imaging (MRI) in glioblastoma can be challenging. For patients with recurrent glioblastoma managed on the CABARET trial, we compared disease status assessed at hospitals and subsequent blinded central expert radiological review. METHODS: MRI results and clinical status at specified time points were used for site and central assessment of disease status. Clinical status was determined by the site. Response Assessment in Neuro-Oncology (RANO) criteria were used for both assessments...
November 8, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29102390/comorbidities-clinical-features-and-prognostic-implications-of-cancer-patients-with-cerebrovascular-disease
#10
Bernardo Cacho-Díaz, Nydia A Lorenzana-Mendoza, Héctor Spínola-Maroño, Gervith Reyes-Soto, Carlos Cantú-Brito
PURPOSE: The objective of this study was to identify and describe the comorbidities, clinical features, and prognostic implications of cancer patients with cerebrovascular disease. MATERIALS AND METHODS: All patients with cerebrovascular disease (CVD) seen in the neuro-oncology unit at a cancer referral center from April 2010 to November 2016 were included; demographic, oncologic diagnosis, risk factors, and prognostic considerations were presented as well. RESULTS: We report on 256 patients with CVD and cancer, of whom 66% were women...
October 25, 2017: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
https://www.readbyqxmd.com/read/29076421/seizures-and-anticonvulsants-in-brain-tumours-frequency-mechanisms-and-anti-epileptic-management
#11
Charles Vecht, Louis Royer-Perron, Caroline Houillier, Gilles Huberfeld
In cancer, epilepsy can be the manifestation of a primary brain tumour, metastatic disease, vascular or surgical complications, opportunistic infection or secondary to anti-tumour therapy. Seizures are frequently the first symptom of a brain tumour. The epilepsy is related to elevated extracellular glutamate stimulating NMDA- and AMPA-receptors and to the formation of D-2HG which resembles glutamate in IDH1 mutated gliomas. Epilepsy as presenting sign is associated with a longer survival in low- and high- grade gliomas, particularly with the IDH1 mutation...
October 27, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/29073725/radiomics-in-paediatric-neuro-oncology-a-multicentre-study-on-mri-texture-analysis
#12
Ahmed E Fetit, Jan Novak, Daniel Rodriguez, Dorothee P Auer, Christopher A Clark, Richard G Grundy, Andrew C Peet, Theodoros N Arvanitis
Brain tumours are the most common solid cancers in children in the UK and are the most common cause of cancer deaths in this age group. Despite current advances in MRI, non-invasive diagnosis of paediatric brain tumours has yet to find its way into routine clinical practice. Radiomics, the high-throughput extraction and analysis of quantitative image features (e.g. texture), offers potential solutions for tumour characterization and decision support. In the search for diagnostic oncological markers, the primary aim of this work was to study the application of MRI texture analysis (TA) for the classification of paediatric brain tumours...
October 26, 2017: NMR in Biomedicine
https://www.readbyqxmd.com/read/29059448/meeting-update-world-federation-of-neuro-oncology-societies-wfnos-meeting-2017
#13
Jaclyn J Renfrow, Michael Weller, Roy E Strowd
No abstract text is available yet for this article.
October 19, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/29049858/adolescents-and-young-adults-with-brain-tumors-in-the-context-of-molecular-advances-in-neuro-oncology
#14
REVIEW
Michal Zapotocky, Vijay Ramaswamy, Alvaro Lassaletta, Eric Bouffet
Adolescents and young adults (AYA) comprise a specific group of oncology patients with a distinct biological and epidemiological spectrum of central nervous system neoplasms. It has been well documented that they differ clinically, especially in relation to prognosis and chemotherapy tolerance; however, the underlying reasons for this are unclear. Recent advances in the genomics of both childhood and adult brain tumors have provided new explanations and insights into the previously described age-dependent heterogeneity...
October 19, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29040703/evidence-and-context-of-use-for-contrast-enhancement-as-a-surrogate-of-disease-burden-and-treatment-response-in-malignant-glioma
#15
Benjamin M Ellingson, Patrick Y Wen, Timothy F Cloughesy
The use of contrast enhancement within the brain on CT or MRI has been the gold standard for diagnosis and therapeutic response assessment in malignant gliomas for decades. The use of contrast enhancing tumor size, however, remains controversial as a tool for accurately diagnosing and assessing treatment efficacy in malignant gliomas, particularly in the current, quickly evolving therapeutic landscape. The current article consolidates overwhelming evidence from hundreds of studies in the field of neuro-oncology, providing the necessary evidence base and specific contexts of use for consideration of contrast enhancing tumor size as an appropriate surrogate biomarker for disease burden and as a tool for measuring treatment response in malignant glioma, including glioblastoma...
October 12, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/29036345/phase-ii-study-of-cabozantinib-in-patients-with-progressive-glioblastoma-subset-analysis-of-patients-with-prior-antiangiogenic-therapy
#16
Timothy F Cloughesy, Jan Drappatz, John de Groot, Michael D Prados, David A Reardon, David Schiff, Marc Chamberlain, Tom Mikkelsen, Annick Desjardins, Jerry Ping, Jaymes Holland, Ron Weitzman, Patrick Y Wen
Background: Cabozantinib is a potent, multi-target inhibitor of hepatocyte growth factor receptor (MET) and vascular endothelial growth factor receptor-2 (VEGFR2). This open-label, phase II trial evaluated cabozantinib in patients with recurrent or progressive glioblastoma (GBM; NCT00704288). Methods: Patients were initially enrolled to a starting cabozantinib dose of 140 mg/day, but the starting dose was amended to 100 mg/day because of safety concerns. Treatment continued until disease progression or unacceptable toxicity...
October 3, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/29016919/challenges-of-developing-small-molecule-kinase-inhibitors-for-brain-tumors-and-the-need-for-emphasis-on-free-drug-levels
#17
Timothy P Heffron
Despite biological rationale and significant clinical study, the pursuit of small molecule kinase inhibitors for the treatment of brain cancers has had very limited success. This Advance-in-Brief discusses the need for drugs to achieve free brain penetration to engage their targets where CNS tumors reside. This need to achieve free, as opposed to total, drug concentrations in the brain may be a contributing factor to why so many small molecule kinase inhibitors have not realized success in the neuro-oncology setting...
September 16, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/29016837/multicenter-pilot-study-of-radio-chemotherapy-as-first-line-treatment-for-adults-with-medulloblastoma-noa-07
#18
Dagmar Dagmar, Martin Proescholdt, Christiane Reinert, Torsten Pietsch, David T W Jones, Stefan M Pfister, Elke Hattingen, Clemens Seidel, Linda Dirven, Ralf Luerding, Jaap Reijneveld, Monika Warmuth-Metz, Matteo Bonsanto, Michael Bremer, Stephanie Combs, Stefan Rieken, Ulrich Herrlinger, Holger Kuntze, Regine Mayer-Steinacker, Dag Moskopp, Thomas Schneider, Andreas Beringer, Uwe Schlegel, Walter Stummer, Helmut Welker, Astrid Weyerbrock, Frank Paulsen, Stefan Rutkowski, Michael Weller, Wolfgang Wick, Rolf-Dieter Kortmann, Ulrich Bogdahn, Peter Hau
Background: Medulloblastoma in adult patients is rare, with 0.6 cases per million. Prognosis depends on clinical factors and medulloblastoma entity. No prospective data on the feasibility of radio-chemotherapy exist. The German Neuro-Oncology Working Group (NOA) performed a prospective descriptive multicenter single-arm Phase II trial to evaluate feasibility and toxicity of radio-polychemotherapy. Methods: The NOA-07 trial combined cranio-spinal irradiation with vincristine, followed by eight cycles of cisplatin, lomustine and vincristine...
August 21, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28988668/-neurophysiological-monitoring-options-in-brain-tumour-resections-consensus-statement-from-the-spanish-society-of-neurosurgery-s-senec-neuro-oncology-working-group-and-the-spanish-society-of-clinical-neurophysiology-senfc
#19
Cristian de Quintana-Schmidt, Estela Lladó-Carbo, Victoria Eugenia Cortés-Doñate
Brain tumours located in or in proximity to eloquent areas are a significant neurosurgical challenge. Performing this kind of surgery with neurophysiological monitoring to improve resections with reduced permanent focal neurological deficit has become widely accepted in the literature. However, how to conduct this monitoring, the exact definition of an eloquent area and whether to perform this surgery with the patient awake or asleep are still subject to rigorous scientific debate. Members of the Neuro-oncology Working Group (GTNO) of the Spanish Society of Neurosurgery (SENEC) and members of the Spanish Society of Clinical Neurophysiology (SENFC) have published a consensus statement to explain the different neurophysiological monitoring options currently available in awake and asleep patients to obtain better surgical resection without neurological deficits...
October 5, 2017: Neurocirugía
https://www.readbyqxmd.com/read/28987677/quantification-accuracy-of-neuro-oncology-pet-data-as-a-function-of-emission-scan-duration-in-pet-mr-compared-to-pet-ct
#20
Stefan Wampl, Ivo Rausch, Tatjana Traub-Weidinger, Thomas Beyer, Martin Gröschl, Jacobo Cal-González
OBJECTIVES: To evaluate and compare the effect of reduced acquisition time, as a surrogate of injected activity, on the PET quantification accuracy in PET/CT and PET/MR imaging. METHODS: Twenty min (18)F-FDG phantom measurements and 10min (18)F-FET brain scans were acquired in a Biograph-True-Point-True-View PET/CT (n=8) and a Biograph mMR PET/MR (n=16). Listmode data were repeatedly split into frames of 1min to 10min length and reconstructed using two different reconstruction settings of a 3D-OSEM algorithm: with post-filtering ("OSEM"), and without post-filtering but with resolution recovery ("PSF")...
October 2017: European Journal of Radiology
keyword
keyword
1438
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"